Moros D - Search Results

1

Criteria to assess in vivo performance and bioequivalence of generic controlled-release formulations of carbamazepine.

Bialer M, Yacobi A, Moros D, Levitt B, Houle JM, Munsaka MS. Bialer M, et al. Among authors: moros d. Epilepsia. 1998 May;39(5):513-9. doi: 10.1111/j.1528-1157.1998.tb01414.x. Epilepsia. 1998. PMID: 9596204 Free article. Clinical Trial.

2

Existing and new criteria for bioequivalence evaluation of new controlled release (CR) products of carbamazepine.

Bialer M, Arcavi L, Sussan S, Volosov A, Yacobi A, Moros D, Levitt B, Laor A. Bialer M, et al. Among authors: moros d. Epilepsy Res. 1998 Nov;32(3):371-8. doi: 10.1016/s0920-1211(98)00064-3. Epilepsy Res. 1998. PMID: 9839777 Clinical Trial.

3

A multiple-dose safety and bioequivalence study of a narrow therapeutic index drug: a case for carbamazepine.

Yacobi A, Zlotnick S, Colaizzi JL, Moros D, Masson E, Abolfathi Z, LeBel M, Mehta R, Golander Y, Levitt B. Yacobi A, et al. Among authors: moros d. Clin Pharmacol Ther. 1999 Apr;65(4):389-94. doi: 10.1016/S0009-9236(99)70132-3. Clin Pharmacol Ther. 1999. PMID: 10223775 Clinical Trial.

4

Who needs individual bioequivalence studies for narrow therapeutic index drugs? A case for warfarin.

Yacobi A, Masson E, Moros D, Ganes D, Lapointe C, Abolfathi Z, LeBel M, Golander Y, Doepner D, Blumberg T, Cohen Y, Levitt B. Yacobi A, et al. Among authors: moros d. J Clin Pharmacol. 2000 Aug;40(8):826-35. doi: 10.1177/00912700022009558. J Clin Pharmacol. 2000. PMID: 10934666 Clinical Trial.

5

The effect of guanethidine on ouabain-induced ventricular arrhythmia in the cat.

Raines A, Moros D, Levitt B. Raines A, et al. Among authors: moros d. Arch Int Pharmacodyn Ther. 1968 Aug;174(2):373-7. Arch Int Pharmacodyn Ther. 1968. PMID: 5727350 No abstract available.

6

The capacity of N-isopropyl-p-nitro-phenylethanolamine (INPEA) to influence the course of ouabain-induced cardiotoxicity in the cat.

Levitt B, Raines A, Moros D, Standaert FG. Levitt B, et al. Among authors: moros d. Eur J Pharmacol. 1969;6(3):217-22. doi: 10.1016/0014-2999(69)90178-2. Eur J Pharmacol. 1969. PMID: 5799184 No abstract available.

7

Temporary microaxial transvalvular left ventricular assist device for post-myocardial infarction ventricular septal rupture: Bridging a paradigm shift.

Moros D, Maigrot JA, Tong MZY, Smedira NG, Soltesz EG, Bakaeen FG, Unai S, Roselli EE, Lee R, Svensson LG, Blackstone EH, Weiss AJ. Moros D, et al. JTCVS Tech. 2024 Sep 4;28:97-108. doi: 10.1016/j.xjtc.2024.08.019. eCollection 2024 Dec. JTCVS Tech. 2024. PMID: 39669340 Free PMC article.

8

Are there etiology-specific risk factors for adverse outcomes in patients on Impella 5.5 support?

Maigrot JA, Thuita L, Tong MZY, Soltesz EG, Smedira NG, Unai S, Starling RC, Higgins A, Moros D, Blackstone EH, Weiss AJ. Maigrot JA, et al. Among authors: moros d. JTCVS Open. 2024 Apr 23;21:123-137. doi: 10.1016/j.xjon.2024.04.014. eCollection 2024 Oct. JTCVS Open. 2024. PMID: 39534347 Free PMC article.

9

Trajectories following Impella 5.5 support are associated with initial presentation acuity.

Maigrot JA, Starling RC, Soltesz EG, Smedira NG, Tong MZY, Unai S, Bhat P, Moros D, Blackstone EH, Weiss AJ. Maigrot JA, et al. Among authors: moros d. Artif Organs. 2025 Jan;49(1):137-145. doi: 10.1111/aor.14867. Epub 2024 Oct 18. Artif Organs. 2025. PMID: 39422190 Free PMC article.

10

A Bioethics Assessment of Continuous Learning in Medicine and AI.

Rhodes R, Darrow B, Moros D, Sacks H, Ostertag G. Rhodes R, et al. Among authors: moros d. Am J Bioeth. 2024 Oct;24(10):72-76. doi: 10.1080/15265161.2024.2388754. Epub 2024 Sep 16. Am J Bioeth. 2024. PMID: 39283376 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

39 results

Search Page

Filters